Agilent Technologies (A)CEO sold ~$227K

~$227K

Approx. value · 2,000 sh @ $113.45

35K

Holds after · shares reported

Traded

Aug 1, 2025

Filed

Aug 4, 2025

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

1. May 12, 2025CongressDisclosed sale of A — reported range $15,001 - $50,000
2. Jun 17, 2025CongressDisclosed purchase of A — reported range $1,001 - $15,000
3. Jun 18, 2025InsiderDirector sold ~$904 of A shares in the open market
4. Jul 1, 2025InsiderCEO sold ~$177K of A shares in the open market
5. Jul 16, 2025CongressDisclosed sale of A — reported range $1,001 - $15,000
6. Aug 1, 2025 · this disclosureInsiderCEO sold ~$227K of A shares in the open market

What came next

1. Aug 11, 2025FDARecall: Brand Name: FLEX Monoclonal Mouse Anti-Human CD20cy, Clone L26, Ready-to-Use (Dako Omnis) Model/Catalog Number: GA60461-2 Software Version: Not applicable Prod…
2. Aug 11, 2025FDARecall: Brand Name: FLEX Monoclonal Mouse Anti-Human CD20cy, Clone L26, Ready-to-Use (Dako Omnis) Model/Catalog Number: GA60461-2J Software Version: Not applicable Pro…
3. Aug 11, 2025FDARecall: Brand Name: FLEX Monoclonal Mouse Anti-Human CD20cy, Clone L26, Ready-to-Use (Dako Omnis) Model/Catalog Number: GA60461-2CN Software Version: Not applicable Pr…
4. Aug 15, 2025FDAFDA device approval: MMR IHC Panel pharmDx (Dako Omnis)
5. Sep 2, 2025InsiderCEO sold ~$250K of A shares in the open market
6. Oct 23, 2025Company filing · Form 8-K · Executive changeChanged a top executive or board member“On October 23, 2025, Agilent Technologies, Inc. (the "Company") appointed Adam S. Elinoff as Senior Vice President and Chief Financial Officer ("CFO") and principal financial officer of the Company effective November 17, 2025 (the "Start Date"), replacing Rodney Gonsalves, who has served as the Company's Interim CFO and Interim Principal Financial Officer since July 31, 2025.”
7. Nov 12, 2025Insider · Their largest sale since 2021CEO sold ~$1.87M of A shares in the open market
8. Nov 18, 2025InsiderCEO sold ~$130K of A shares in the open market
9. Nov 24, 2025Company filing · Form 8-K · ResultsReported its results

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Agilent Technologies

For Agilent Technologies, OQRO holds 2 insider filings (SEC Form 4 or Form 144), 2 Congress trade reports, 21 fund holdings reports (13F) and 6 federal contract awards dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its A page.

Other recent filings by Padraig Mcdonnell, President and CEO

• SEC Form 4 at Agilent Technologies (A)Nov 20, 2025
• SEC Form 4 at Agilent Technologies (A)Nov 14, 2025
• SEC Form 4 at Agilent Technologies (A)Sep 4, 2025
• SEC Form 4 at Agilent Technologies (A)Jul 3, 2025
• SEC Form 4 at Agilent Technologies (A)Jan 24, 2025

The full history of Padraig Mcdonnell, President and CEO is on the profile page.

How this filing works

• SEC Form 4
• Open-market purchase
• Rule 10b5-1 trading plans

Other disclosures at Agilent Technologies

• USAspending.gov award recordSep 29, 2026
• USAspending.gov award recordSep 28, 2026
• SEC Form 4Sep 9, 2026
• SEC Form 144Sep 4, 2026
• USAspending.gov award recordAug 18, 2026
• SEC Form 13F-HRAug 14, 2026

Everything OQRO holds on this company is on its A page.